Vranjkovic et al.66 found that HCV-infected patients with pronounced liver fibrosis (F4) displayed hyperfunctional activity of peripheral CD8+ T-cell subsets sustained up to a year after treatment, and the impact of successful DAA therapy on T-cell activation depended largely on the stage of liver fibrosis. This evidence concerns the gene CD8A and Hepatic fibrosis.